NeuroPace (NPCE) Cash & Equivalents Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 72.43% |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | -45.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.15% |
| Mar 31, 2026 | -45.30% |
| Dec 31, 2025 | 61.52% |
| Sep 30, 2025 | 33.92% |
| Jun 30, 2025 | 77.96% |
| Mar 31, 2025 | 107.87% |
| Dec 31, 2024 | -25.63% |
| Sep 30, 2024 | 58.67% |
| Jun 30, 2024 | 63.51% |
| Mar 31, 2024 | 93.42% |
| Dec 31, 2023 | 173.40% |
| Sep 30, 2023 | 70.83% |
| Jun 30, 2023 | 37.76% |
| Mar 31, 2023 | -10.27% |
| Dec 31, 2022 | -65.58% |
| Sep 30, 2022 | -78.64% |
| Jun 30, 2022 | -81.75% |
| Mar 31, 2022 | -45.89% |
| Dec 31, 2021 | -27.29% |
| Sep 30, 2021 | -38.26% |